Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
Insight Lifetech, a Qiming Venture Partners‑backed innovative medical device manufacturer, has listed on the Shanghai...
IPO
Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics
Knature Biopharmaceutical Co., Ltd., a China‑based biopharma specializing in mitochondrial medicine, has submitted its initial...
TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline
TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board...
PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform
PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immuno‑inflammation biotech founded in 2016, made an initial public...
Zenshine Pharma Files for Hong Kong IPO with $357M Valuation
Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main...
Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611
Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong...
Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21
Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong...
Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing
Distinct Healthcare Holdings Limited, a China‑based private healthcare service provider, released its prospectus this week...
Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader
Acrobiosystems Co., Ltd. made its initial public offering filing to the Hong Kong Stock Exchange,...
Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline
Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong...
Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
Knature Biopharmaceutical Co., Ltd. announced it has filed for an initial public offering (IPO) with...
Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets
Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China‑based joint venture established by AstraZeneca (AZ, NASDAQ: AZN)...
PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immune‑inflammatory disease specialist founded in 2016, has filed for...
BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline
Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong...
Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform
Hangzhou Diagens Biotechnology Co., Ltd. announced a filing for an initial public offering (IPO) to...
InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
InventisBio Co., Limited (SHA: 688382) this week filed for an initial public offering (IPO) to...
Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange...
Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on...
Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO
Simcere Pharmaceutical Group Limited (HKG: 2096) announced plans to spin off its subsidiary Simcere Zaiming...
Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock...